scholarly journals Infliximab Therapy Provides Beneficial Effects for Choroidal Thickness Increase in Patients With Active Ankylosing Spondylitis: A Possible Mechanism Mediating the Suppressing of Uveitis Attacks

2020 ◽  
Author(s):  
Murat KARKUCAK ◽  
Mehmet KOLA ◽  
Ahmet KALKIŞIM ◽  
Erhan ÇAPKIN ◽  
Ahmet AYAR ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Choroidal Thickness ◽  
Infliximab Therapy ◽  
Thickness Increase ◽  
Beneficial Effects

scholarly journals Successful Treatment of AA Amyloidosis in Ankylosing Spondylitis Using Tocilizumab: Report of Two Cases and Review of the Literature

2021 ◽  
Vol 8 ◽  
Author(s):  
Per Eriksson ◽  
Johan Mölne ◽  
Lina Wirestam ◽  
Christopher Sjöwall
Keyword(s):  
Ankylosing Spondylitis ◽  
Therapeutic Option ◽  
Relevant Literature ◽  
Acute Phase Reactant ◽  
Renal Amyloidosis ◽  
Secondary Amyloidosis ◽  
Aa Amyloidosis ◽  
Beneficial Effects ◽  
Amyloid A ◽  
Inflammatory Conditions

Historically, secondary amyloidosis has been a feared complication of chronic inflammatory conditions. The fibril protein AA derives from the acute phase reactant serum amyloid A (SAA). Long-term elevation of SAA levels remains a major risk factor for the development of AA amyloidosis in rheumatic diseases, and the prognosis may be unpredictable. Nowadays, with increased availability of effective biological agents, the incidence of AA amyloidosis seems to be declining. Still, genetically predisposed subjects with slowly progressive disease and mild symptoms combined with ongoing systemic inflammation may be at risk. Interleukin-6 (IL-6) is one of the drivers of SAA release and effectiveness of the humanized anti-IL-6 receptor antibody tocilizumab (TCZ) for the treatment of AA amyloidosis has been observed in some rheumatic conditions. Herein, we report two male subjects with longstanding ankylosing spondylitis (AS) complicated by renal amyloidosis who received TCZ with rapid and beneficial effects regarding inflammation and proteinuria. To the best of our knowledge, the use of TCZ in AS patients with this extra-articular manifestation has not previously been described. The paper includes histopathology, clinical follow-up, and longitudinal data of the two cases along with a comprehensive review of relevant literature. Mechanisms behind amyloid-mediated tissue damage and organ dysfunction are discussed. Altogether, our data highlight that blocking IL-6 signaling may represent a promising therapeutic option in patients with renal AA amyloidosis.

Paraparesis due to exacerbation of preexisting spinal pseudoarthrosis following infliximab therapy for advanced ankylosing spondylitis

2006 ◽  
Vol 6 (3) ◽  
pp. 325-329 ◽  
Author(s):  
Hironobu Sakaura ◽  
Noboru Hosono ◽  
Yoshihiro Mukai ◽  
Ryutaro Fujii ◽  
Hideki Yoshikawa
Keyword(s):  
Ankylosing Spondylitis ◽  
Infliximab Therapy

Effects of Homoeopathic Single and Minimum Dose on Non-Radiographic Axial Spondyloarthritis—BASDAI Assessment

2020 ◽  
Vol 33 (01) ◽  
pp. 041-052
Author(s):  
Deepak Kumar ◽  
Eiphrangdaka L. Suchiang ◽  
Gautam Pal
Keyword(s):  
Ankylosing Spondylitis ◽  
Axial Spondyloarthritis ◽  
Activity Index ◽  
Disease Activity Index ◽  
Low Back ◽  
Beneficial Effects ◽  
Mild Disease ◽  
Minimum Dose ◽  
Before And After ◽  
Activity Index Score

AbstractEarly cases of ankylosing spondylitis do not have the typical presentation of radiographic sacroiliitis but present as non-radiographic axial spondyloarthritis (nr-axSpA) where both are varieties of axSpA. Homoeopathic prescription based on totality of symptoms offers a promising relief to nr-axSpA where peripheral joints are also affected. Here, a 27-year-old male patient presented with bilateral heel pain, pain in low back, pain on base of right toes, pain in neck with stiffness for 1 year had refractive response to conventional medication. Diagnosis was confirmed by Assessment of SpondyloArthritis International Society diagnostic criteria for axSpA. Single medicine and minimum dose of Silicea showed its effectiveness on the symptoms' improvement and Bath Ankylosing Spondylitis Disease Activity Index score whereby score of 8.8 (active disease) before treatment changed to 1.2 (inactive or mild disease) after treatment. Various other parameters were assessed accordingly before and after treatment. This case report encourages further exploring the beneficial effects of homoeopathic treatment in clinical condition like axSpA utilising validated scale.

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

2008 ◽  
Vol 58 (10) ◽  
pp. 3063-3070 ◽  
Author(s):  
Désirée van der Heijde ◽  
Robert Landewé ◽  
Xenofon Baraliakos ◽  
Harry Houben ◽  
Astrid van Tubergen ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Infliximab Therapy ◽  
Radiographic Findings

Infliximab Therapy for Inflammatory Discitis in Ankylosing Spondylitis

2012 ◽  
Vol 18 (2) ◽  
pp. 109-110 ◽  
Author(s):  
Nilay Joshi ◽  
Amit Nautiyal ◽  
Tom Walton
Keyword(s):  
Ankylosing Spondylitis ◽  
Infliximab Therapy
Sign in / Sign up

Export Citation Format

Share Document